Turning Point Therapeutics stock more than doubles after Bristol Myers buyout deal valuing company at $3.8 billion
Shares of Turning Point Therapeutics Inc. more than doubled, up 116.7%, in premarket trading Friday, after the clinical-stage oncology company agreed to be acquired by...